Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6MZP7
UPID:
LIN54_HUMAN
Alternative names:
CXC domain-containing protein 1
Alternative UPACC:
Q6MZP7; Q32M68; Q32M69; Q6N071; Q76B60
Background:
Protein lin-54 homolog, also known as CXC domain-containing protein 1, plays a pivotal role in cell cycle regulation. It is a crucial component of the DREAM complex, which functions as a transcription activator or repressor depending on the cell cycle phase. This protein is essential for the repression of E2F target genes in G0 phase and activates G2/M genes necessary for mitosis in S phase. It specifically binds to the promoter of CDK1, recognizing the consensus motif 5'-TTYRAA-3'.
Therapeutic significance:
Understanding the role of Protein lin-54 homolog could open doors to potential therapeutic strategies.